By Erika Matich | University Communications
AURORA, Colo. – Clinicians and researchers from the University of Colorado Anschutz Medical Campus are heading to Chicago at the beginning of June to attend the annual gathering of the American Society of Clinical Oncology (ASCO).
Several faculty members will be presenting at the conference including Robert Doebele, MD, PhD; Wilbur Franklin, MD; Marileila Varella-Garcia, PhD; Daniel W. Bowles, MD; Antonio Jimeno, MD, PhD; Murry W. Wynes, PhD; D. Ross Camidge, MD, PhD; Andrew Weickhardt, MD; and Anthony Elias, MD.
The University of Colorado Cancer Center leads the way in lung cancer research, so it may be no surprise that much of the research comes from that area.
Camidge and Doebele continue their work on drug resistance in non-small cell lung cancer (NSCLC). Franklin looked at genetic testing to accompany CT screens as way to diagnose lung cancer in its early stages. Garcia identified a new subset of lung cancer patients that may benefit from a targeted therapy. Wynes looked at two phase III studies retrospectively to determine if patients with NSCLC may have benefited from biomarker identification before beginning specific therapies.
In addition to presentations by these CU scientists and others from across the country, the National Cancer Institute (NCI) will be hosting dozens of education sessions on subjects such as obesity and cancer risk and why more people don’t alter behaviors known to increase the risk of cancer. Many of the educational sessions at ASCO’s annual meeting will highlight the selected questions posed by the NCI. ASCO also identified five things patients and oncologists should question.
ASCO is a medical professional society committed to conquering cancer through research, education, prevention and delivery of high-quality patient care. ASCO recognizes the importance of evidence-based cancer care and making wise choices in the diagnosis and management of patients with cancer.